Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients have?
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients has 345 citations in the OpenAlex counts ScholarIQ stores.
When was Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients published?
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients has 2015 year in the ScholarIQ index.
What is the open-access status of Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients?
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients has bronze oa status in the ScholarIQ index.
What is the DOI of Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients?
The DOI for Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients is on the source record.
What is the PMID of Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients?
The PMID for Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients is on the source record.
What is the OpenAlex record for Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients?
The OpenAlex for Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients is on the source record.